Personal Investment Vitae

Home > Personal Investment Vitae

AYA Personal Investment Vitae as of January 2026
Joseph Corr @Joseph Corr
Platinum member since January 2017

Location: United States

Gender: Male

Asset investment style: Qualitative fundamental analysis

Market capitalization:

$7,991,718talents

Virtual portfolio value:

$5,041,410talents

Net overall return per annum:

19.55%

AYA current rank order:

#17

Asset investment philosophy:
Joseph Corr trades U.S. stocks with the top #301 to #500 positive alpha signals.

Top 10 profitable stock transactions since January 2020Strategy

Symbol Company Buy Sell Share Volume Return (%) Profit ($)
SXTP 60 Degrees Pharmaceuticals Inc. Common Stock $0.15 $1.34 110,866 +793.33% $131,931
VATE INNOVATE Corp. Common Stock $0.53 $4.14 31,377 +681.13% $113,271
XBIOW Xenetic Biosciences Inc. Warrants $2.00 $23.16 4,407 +1,058.00% $93,252
RMBL RumbleOn Inc. Class B Common Stock $0.36 $7.95 9,200 +2,108.33% $69,828
LSCC Lattice Semiconductor Corporation Common Stock $6.97 $48.04 1,387 +589.24% $56,964
HZNP Horizon Therapeutics Public Limited Company Ordinary Shares $16.41 $98.56 589 +500.61% $48,386
TUEM Tuesday Morning Corp. Common Stock $0.12 $0.69 74,858 +475.00% $42,669
NTZ Natuzzi S.p.A. $2.21 $11.92 4,376 +439.37% $42,491
MRNS Marinus Pharmaceuticals Inc. Common Stock $1.94 $11.62 2,308 +498.97% $22,341
BBX BBX Capital Corporation $2.54 $14.54 1,545 +472.44% $18,540
Sum $639,673

Blog+More

Just Capital issues a new report in support of the stakeholder value proposition in recent times.

Amy Hamilton

2018-06-05 07:36:00 Tuesday ET

Just Capital issues a new report in support of the stakeholder value proposition in recent times.

Just Capital issues a new report in support of the stakeholder value proposition in recent times. U.S. corporations that perform best on key priorities such

+See More

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fundamental analysis of AT&T (U.S. stock symbol: $T).

Apple Boston

2025-10-05 17:31:00 Sunday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fundamental analysis of AT&T (U.S. stock symbol: $T).

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund

+See More

Stock Synopsis: ESG value and momentum stock market portfolio strategies

Fiona Sydney

2024-03-26 09:30:00 Tuesday ET

Stock Synopsis: ESG value and momentum stock market portfolio strategies

Stock Synopsis: ESG value and momentum stock market portfolio strategies Since 2013, we have been delving into the broad topics of ESG (Environmental, So

+See More

The Trump $1.5 trillion hefty tax cuts and $1 trillion infrastructure expenditures may speed up the Federal Reserve interest rate hike.

Joseph Corr

2018-03-15 07:41:00 Thursday ET

The Trump $1.5 trillion hefty tax cuts and $1 trillion infrastructure expenditures may speed up the Federal Reserve interest rate hike.

The Trump administration's $1.5 trillion hefty tax cuts and $1 trillion infrastructure expenditures may speed up the Federal Reserve interest rate hike

+See More

Eric Posner and Glen Weyl propose radical reforms to resolve key market design problems for better democracy and globalization.

Chanel Holden

2023-02-14 09:31:00 Tuesday ET

Eric Posner and Glen Weyl propose radical reforms to resolve key market design problems for better democracy and globalization.

Eric Posner and Glen Weyl propose radical reforms to resolve key market design problems for better democracy and globalization. Eric Posner and Glen Weyl

+See More

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Rose Prince

2018-10-15 09:33:00 Monday ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications an

+See More